NT5E and pancreatic adenocarcinoma: Moreover, CD73 overexpression has been implicated with a poor prognosis and resistance to checkpoint inhibition, making it a potential biomarker and therapeutic target in cancers including pancreatic adenocarcinoma [107,108].